@entity9242 PET/CT as a complementary tool in the follow-up of XXXX : diagnostic accuracy and clinical utility.

@entity11 @entity1 @entity5 @entity9242
PURPOSE: The follow-up of treated @entity11 ( @entity11 ) requires the evaluation of subtle clinical changes and MRI results. When the result is inconclusive, additional procedures are required to assist decision-making, such as the use of advanced MRI (aMRI) sequences and nuclear medicine scans (SPECT and PET). The aim of this study was to determine whether incorporating @entity9242 PET/CT in the follow-up protocol for treated @entity11 improves diagnostic accuracy and clinical utility. METHODS: This was a prospective case-series study in @entity1 with treated @entity11 during standard follow-up with indeterminate clinical and/or radiological findings of @entity5 activity. All @entity1 underwent clinical evaluation, aMRI, (201)Tl-SPECT and @entity9242 PET/CT. Images were interpreted by visual evaluation complemented with semiquantitative analysis. RESULTS: Between January 2012 and December 2013, 18 @entity1 were included in this study. The final diagnosis was established by histology (five surgical specimens, one biopsy specimen) or by consensus of the Neuro-Oncology Group (11 @entity1 ) after a follow-up of >6  months (mean 14.9        2.72  months). The global diagnostic accuracies were 90.9  % for aMRI (38.8  % inconclusive), 69.2  % for (201)Tl-SPECT (11.1  % inconclusive), and 100  % for @entity9242 PET/CT. (201)Tl-SPECT led correctly to a change in the initial approach in 38.9  % of @entity1 but might have led to error in 27.8  %. The use of @entity9242 PET/CT alone rather than (201)Tl-SPECT led correctly to a change in the approach suggested by routine follow-up in 72.2  % of @entity1 and endorsed the approach in the remaining 27.8  %. CONCLUSION: Our results support the need to complement structural MRI with aMRI and nuclear medicine procedures in selected @entity1 . @entity9242 PET/CT can be useful in the individualized management of @entity1 with treated @entity11 with uncertain clinical and/or radiological evidence of @entity5 activity.
